옵션 체인은 다양한 행사가격과 만기일에 대한 CureVac의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 CureVac에 대한 시장 심리를 평가합니다..

CureVac (NASDAQ:CVAC) 주식, 옵션 체인

CureVac

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Virus,Sample,For,H5n1,(avian,Influenza,Virus),Test,,Avian,Influenza

Large Cap

News

Health Care

General

CVAC

MRNA

NVAX

네바다의 한 낙농업자가 1월에 루이지애나 남자의 사망과 관련된 조류 독감 D1.1 변종에 양성 반응을 보였다고 CNN이 보도했다. 미국 질병통제예방센터(CDC)는 월요일에 초기 양성 반응을 확인하기 위해 작업 중이다.

네바다 남성에서 발견된 치명적인 조류 독감 변종: 주목해야 할 4가지 주식

CureVac NV

The reverse stock split will become effective at 4:30 p.m. Eastern Time on March 21, 2025, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on March 24, 2025.&nbsp;

Stock Split

ZCAR

Zoomcar Plans 1-For-20 Reverse Stock Split

Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) has outperformed the market over the past 5 years by 11.0% on an annualized basis producing an average annual return of 29.46%. Currently, Primerica has a market capitalization of $9.66 billion. 
Buying $1000 In PRI: If an investor had bought $1000 of PRI stock 5 years ago, it would be worth $4,288.53 today based on a price of $289.39 for PRI at the time of writing.
<h3>Primerica's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742418914_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Primerica 5 Years Ago Would Be Worth This Much Today

<h3>Gainers</h3>
<ul>
<li>SAG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) shares rose 23.7% to $0.83 during Wednesday's after-market session. The company's market cap stands at $8.2 million. </li>
<li>Aureus Greenway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock moved upwards by 23.05% to $0.99. The market value of their outstanding shares is at $13.7 million. </li>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) shares moved upwards by 12.63% to $0.2. The market value of their outstanding shares is at $10.3 million. </li>
<li>Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) shares moved upwards by 8.21% to $81.8. The company's market cap stands at $4.4 billion. The company's, Q4 earnings came out today. </li>
<li>Nxu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares rose 5.95% to $0.25. The market value of their outstanding shares is at $6.0 million. </li>
<li>Lakeland Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) stock moved upwards by 4.95% to $19.92. The market value of their outstanding shares is at $189.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock declined by 7.0% to $0.13 during Wednesday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) stock fell 5.02% to $0.41. The market value of their outstanding shares is at $8.2 million. </li>
<li>CarParts.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTS#NASDAQ">PRTS</a>) stock fell 5.0% to $0.96. The company's market cap stands at $51.4 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares decreased by 4.83% to $0.38. The market value of their outstanding shares is at $6.1 million. </li>
<li>Newton Golf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTG#NASDAQ">NWTG</a>) shares fell 4.47% to $2.14. </li>
<li>Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) stock decreased by 4.4% to $10.63. The market value of their outstanding shares is at $942.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIEV

FIVE

LAKE

NWTG

PRTS

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares rose 14.6% to $1.81 during Wednesday's after-market session. The company's market cap stands at $10.3 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock moved upwards by 11.0% to $2.22. The market value of their outstanding shares is at $2.4 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 8.43% to $0.45. The market value of their outstanding shares is at $2.2 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares moved upwards by 6.36% to $0.62. The market value of their outstanding shares is at $52.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares rose 6.11% to $0.22. The market value of their outstanding shares is at $6.6 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares moved upwards by 5.7% to $0.38. The company's market cap stands at $38.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 20.4% to $2.26 during Wednesday's after-market session. The market value of their outstanding shares is at $533.8 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock declined by 7.54% to $1.35. The market value of their outstanding shares is at $39.9 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 6.63% to $0.27. The market value of their outstanding shares is at $1.6 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock declined by 6.32% to $1.78. The company's market cap stands at $15.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 6.03% to $3.05. The market value of their outstanding shares is at $2.0 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock declined by 5.96% to $24.0. The market value of their outstanding shares is at $660.0 million. As per the news, the Q4 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKBA

APDN

BCLI

DYAI

FGEN

IPSC

LENZ

SCNX

SHPH

VERO

Longevity Health Holdings, Inc. - Common Stock

XAGE

YCBD

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) stock increased by 10.4% to $0.85 during Wednesday's after-market session. The market value of their outstanding shares is at $42.8 million. </li>
<li>ConnectM Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) stock moved upwards by 9.19% to $0.66. The company's market cap stands at $19.2 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock moved upwards by 8.25% to $2.73. The market value of their outstanding shares is at $91.1 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) shares rose 6.92% to $0.22. The market value of their outstanding shares is at $12.3 million. </li>
<li>Optex Systems Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPXS#NASDAQ">OPXS</a>) stock increased by 6.36% to $6.02. The company's market cap stands at $41.5 million. </li>
<li>Marwynn Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) shares increased by 5.0% to $4.2. The market value of their outstanding shares is at $71.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) shares fell 13.2% to $0.23 during Wednesday's after-market session. The market value of their outstanding shares is at $10.3 million. </li>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) stock fell 8.59% to $1.81. The market value of their outstanding shares is at $26.9 million. </li>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) shares fell 6.41% to $1.17. The market value of their outstanding shares is at $19.0 million. </li>
<li>Founder Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGL#NASDAQ">FGL</a>) shares declined by 4.67% to $1.43. The company's market cap stands at $24.1 million. </li>
<li>Hyliion Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#AMEX">HYLN</a>) shares fell 4.22% to $1.59. The company's market cap stands at $277.9 million. </li>
<li>DLH Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLHC#NASDAQ">DLHC</a>) shares decreased by 3.8% to $4.56. The company's market cap stands at $65.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLIK

CLIR

CNTM

DLHC

DXST

HYLN

MWYN

Nuveen Insured California Premium Fund Ii

NEOV

OPXS

PITA

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cemtrex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) stock moved upwards by 5.6% to $1.69 during Wednesday's after-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Sigmatron Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) shares rose 5.12% to $1.23. The company's market cap stands at $7.5 million. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) shares rose 5.01% to $3.56. The company's market cap stands at $37.5 million. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares increased by 4.97% to $0.2. The market value of their outstanding shares is at $13.9 million. </li>
<li>SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) shares moved upwards by 4.94% to $20.94. The company's market cap stands at $11.6 billion. </li>
<li>Backblaze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLZE#NASDAQ">BLZE</a>) stock increased by 4.89% to $5.79. The market value of their outstanding shares is at $314.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares fell 8.7% to $0.31 during Wednesday's after-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares decreased by 7.64% to $3.51. The company's market cap stands at $8.3 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) shares declined by 5.76% to $0.2. The market value of their outstanding shares is at $5.1 million. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares declined by 5.39% to $0.25. The market value of their outstanding shares is at $11.3 million. </li>
<li>Syntec Optics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) stock fell 4.67% to $1.43. The company's market cap stands at $52.4 million. </li>
<li>Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) stock decreased by 4.06% to $7.58. The market value of their outstanding shares is at $117.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

AIXI

BLZE

CETX

CSAI

GRYP

OPTX

SAIL

SGMA

12 Information Technology Stocks Moving In Wednesday's After-Market Session

VCYT

Veracyte Plans To Present Multiple Abstracts At EAU25 Demonstrating Clinical Performance And Utility Of Its Decipher Tests In Prostate And Bladder Cancer

The Federal Reserve left interest rates unchanged at 4.25%-4.50% on Wednesday, with Chairman Jerome Powell reviving the term &#8220;transitory&#8221; to describe the potential inflationary <a href="https://www.benzinga.com/topic/tariffs">effects of new tariffs.</a>
While the Fed still projects two rate cuts in 2025 in its latest dot plot, projections now reflect lower growth and higher inflation, fueling renewed concerns about stagflation.
Economists are increasingly skeptical of the Fed's confidence in inflation easing, with some warning of policy missteps and rising recession risks.
Here's a summary of key reactions from leading economists.
<h3 class="wp-block-heading">‘Transitory' Is Back: A Risky Assumption</h3>
Allianz chief economic adviser Mohamed El-Erian criticized Powell's use of &#8220;transitory&#8221; to describe tariff-driven inflation, recalling the Fed's 2022 mistake when it downplayed persistent price pressures.
&#8220;It's simply too early to say with any degree of confidence that the inflationary effects will be transitory,&#8221; El-Erian said, adding that businesses and households &#8220;still have fresh in their minds the recent history of high unanticipated inflation.&#8221;
Given the uncertainties, he expected Fed officials to show &#8220;greater humility.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The word — "transitory" — is back at the Federal Reserve as Chair Powell characterizes the price effects of tariffs as a one-off. I would have thought that, particularly after the big policy mistake of earlier this decade and given all the current uncertainties, some Fed…
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1902435256927388049?ref_src=twsrc%5Etfw">March 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Kobeissi Letter ridiculed Powell's response to stagflation concerns, recalling a past press conference where he dismissed the risk, saying he wasn't seeing the &#8220;stag&#8221; or the &#8220;flation.&#8221; Yet, that stance now appears contradictory, as the Fed's latest projections show slower GDP growth alongside rising inflation and unemployment.
&#8220;We are now seeing the &#8216;stag&#8217; and the &#8216;flation&#8217;.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This clip is from almost exactly 11 months ago: Fed Chair Powell was asked about stagflation and he said he&#39;s not seeing the &quot;stag&quot; or the &quot;flation.&quot; Today, the Fed raised both unemployment and inflation forecasts for 2025, while cutting GDP growth estimates. We are now seeing… <a href="https://t.co/w5c35jnIWa">pic.twitter.com/w5c35jnIWa</a>
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1902423342709412138?ref_src=twsrc%5Etfw">March 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Mixed Signals On Inflation And Growth</h3>
Jeffrey Roach, chief economist at LPL Financial, said the Fed&#8217;s decision was unsurprising, as policymakers are &#8220;in the midst of policy fog&#8221; while awaiting the impact of upcoming tariffs. 
He highlighted that despite upside risks in recent inflation data, core inflation should decelerate by summer, allowing the Fed to begin cutting rates in June.
Steve Wyett, chief investment strategist at BOK Financial, stressed the uncertainty arising from the Fed&#8217;s forecasts.
&#8220;The Fed remains as confused as the rest of us as to what the impact of policy changes will be,&#8221; he said. 
Charlie Ripley, senior investment strategist at Allianz Investment Management, highlighted the Fed's struggle to balance growth and inflation expectations.
&#8220;Growth appeared to be downgraded more than the uptick of inflation expectations, yet the pace of expected rate cuts remained the same,&#8221; he said, pointing to continued uncertainty around inflation. Yet, the Fed's decision to slow the run-off of its balance sheet in April provided &#8220;some consolation&#8221; for investors.
<h3 class="wp-block-heading">Recession Warnings Grow Louder</h3>
David Rosenberg, president of Rosenberg Research &amp; Associates Inc., indicates the Fed's updated unemployment forecast is a strong recession indicator. He noted that the Fed now sees unemployment rising to 4.4% by year-end, which historically signals an economic downturn.
&#8220;Back to 1948, that has never happened without an NBER-defined recession,&#8221; Rosenberg said, referring to the National Bureau of Economic Research, which officially declares U.S. recessions. 
He warned that if past trends hold, a recession could materialize as early as July, well before the Fed takes any significant action.
<h3 class="wp-block-heading">Is Powell Too Dovish?</h3>
Spencer Hakimian, founder of Tolou Capital Management, described Powell as &#8220;very dovish,&#8221; suggesting the Fed is either underestimating inflation risks or &#8220;hoping for a miracle.&#8221;
&#8220;They see higher inflation. But they&#8217;re projecting two more rate cuts,&#8221; he said, calling the approach a &#8220;heads I win, tails you lose&#8221; scenario. Despite his concerns, Hakimian remains bullish on risk assets, advising investors to stay &#8220;long a good amount of risk,&#8221; with 40-50% exposure.
<h3 class="wp-block-heading">Market Reaction</h3>
Despite concerns from economists, Powell's remarks fueled a risk-on rally. 
The S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – closed 1.1% higher on Wednesday, while the tech-heavy Nasdaq 100 jumped 1.4%. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged past $85,000, and gold extended record highs, rising 0.5% to $3,050 per ounce.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44400742/nvidias-very-strong-roadmap-wins-praise-from-7-analysts-on-blackwell-robotics-ai-growth">Nvidia&#8217;s &#8216;Very Strong Roadmap&#8217; Wins Praise From 7 Analysts On Blackwell, Robotics, AI Growth</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

$BTC

Economists React To Powell: 'We Are Now Seeing The Stag And The Flation'

Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) shares traded higher on Wednesday driven by overall market strength following the Federal Reserve&#8217;s decision to <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44403637/fed-holds-rates-while-growth-forecasts-slip-inflation-projections-rise">hold interest rates steady</a>.
What To Know: The Fed opted to hold the federal funds rate at a range of 4.25% to 4.50% at its Wednesday meeting, suggesting that the economy remains healthy enough to leave rates unchanged. 
The central bank's March statement highlighted that the economy continues to grow at a strong pace and the labor market remains solid, but inflation pressures are still present. The Fed also acknowledged increased uncertainty around the economic outlook, but took a less hawkish stance overall, which appears to have boosted broader markets.
The Fed&#8217;s latest economic projections were also a key factor contributing to market movement. GDP growth forecasts for 2025 were revised downward to 1.7%, from an earlier projection of 2.1%. 
At the same time, inflation expectations were raised. The core Personal Consumption Expenditures (PCE) price index, which excludes volatile food and energy prices, was adjusted up to 2.7% for 2025, from the previous forecast of 2.5%. This shift in projections pointed to rising concerns about stagflation, which occurs when the economy experiences slow growth combined with high inflation.
Despite the inflation concerns, the Fed's outlook also included expectations for two interest rate cuts in both 2025 and 2026. Fed Chair Jerome Powell also downplayed recent surveys that have pointed to rising uncertainty among households and businesses. 
"We think our policy is in a good place," Powell said in a press conference Wednesday.
Shopify announced this week that it will voluntarily transfer its U.S. stock exchange listing from the New York Stock Exchange to the Nasdaq. The company&#8217;s shares will commence trading on the Nasdaq on March 31.
Price Action: Shopify shares closed Wednesday up 8.19% at $101.71, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent071824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="555" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/19160704/Screenshot-2025-03-19-at-16.06.39-1024x555.png" alt="" class="wp-image-832381" style="width:404px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/19160704/Screenshot-2025-03-19-at-16.06.39-1024x555.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/19160704/Screenshot-2025-03-19-at-16.06.39-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/19160704/Screenshot-2025-03-19-at-16.06.39-768x416.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/19160704/Screenshot-2025-03-19-at-16.06.39.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44405112/tariff-inflation-may-be-transitory-powell-says-stocks-rally-bitcoin-clears-85000-as-bulls-return">Tariff Inflation May Be &#8216;Transitory,&#8217; Powell Says: Stocks Rally, Bitcoin Clears $85,000 As Bulls Return</a>&#8216;</li>
</ul>
Image via Shutterstock.

SHOP

Shopify Shares Climbed 8% Wednesday: What Happened?

Under the NCIB program, the Company is authorized to purchase up to 110.35 million of its common shares, representing up to 10% of the Company's public float, during the period starting on March 24, 2025 and ending on March 23, 2026.

Buybacks

Kinross Reports Renewal Of Normal Course Issuer Bid Program For Up To 10% Of Public Float

A senior developer who had been loyal to a startup for three years learned the hard way that company loyalty doesn't always pay off. After <a href="https://www.benzinga.com/personal-finance/25/03/44207260/his-boss-loves-him-a-redditors-friend-refused-a-5k-raise-convinced-it-would-mean-less-money-after-taxes">asking for a raise</a> to help support his growing family, he was quickly replaced with a cheaper worker. Now, he's fully <a href="https://www.benzinga.com/news/25/01/43346851/surprisingly-feasible-software-engineer-shares-how-a-175k-second-job-helped-him-save-20k-in-just-two-months">embracing the &#8220;overemployed&#8221; lifestyle</a> and vows never to rely on just one job again.
<h2 class="wp-block-heading">A Tough Lesson In Job Security</h2>
The developer <a href="https://www.reddit.com/r/overemployed/comments/1jab7k7/never_quitting_oe_again/">shared</a> his story on Reddit, explaining how he had joined a small <a href="https://www.benzinga.com/money/how-to-invest-in-startups">startup</a> three years ago. As a contractor outside the U.S., he wasn't eligible for stock options but worked hard to help the company grow.
"There was a lot to be done, and boy, I did deliver <a href="https://in.benzinga.com/personal-finance/25/02/43820555/tech-ceo-calls-working-two-jobs-a-form-of-theft-and-deception-fires-engineers-earning-140000-for-holding-secret-second-full-time-jobs">even with a J2</a>," he wrote, referring to his second job.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Hasbro, MGM Resorts, and Sketchers Use this Pre-IO AI Marketing Firm — <a href="https://www.benzinga.com/money/rad-intel">and You Can Own a Piece of it From $0.55/Share</a></li>
</ul>
Over the years, the company became highly profitable, but his compensation barely changed—just a 2% raise in total. Despite that, he stayed because he liked the team.
Things changed in November when he found out his wife was pregnant. Wanting to prioritize his family and health, he decided to quit his second job and focus on his primary employer. At the start of the year, he requested a 15% raise, explaining that inflation had eaten into his earnings and that the company could afford it.
Fifteen days later, one of the company's founders scheduled a meeting. The message was harsh: They had found someone cheaper and <a href="https://www.benzinga.com/news/25/03/44277188/a-poverty-sentence-heres-why-some-say-losing-a-federal-job-is-worse-than-being-fired-in-the-private-sector">no longer needed his services</a>.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">Embracing The Overemployed Lifestyle</h2>
After losing his job so suddenly, the developer quickly secured a new position. Not stopping there, he also lined up a second job and is considering adding a third.
"Never again will I be relying [on] the safety of my family on a single [employer]," he wrote.
His story resonated with many online, with commenters sharing similar experiences of being let go despite years of dedication. Others encouraged him to embrace the benefits of working multiple remote jobs.
One user shared a strikingly similar experience: "I casually requested 2 weeks holiday in advance due to my son being born. They responded with a &#8216;You are fired&#8217; 1 week before he was born. We were literally at the bottom for months because of this because I was not OEing then."
See Also: This Startup Is On The Brink Of A Huge Disruption To The $654 Billion Industry – <a href="https://www.benzinga.com/money/venhub-adv">Invest In It Before It Fulfills 800 Pre-Orders</a>
Another pointed out how companies exploit workers whenever they can: "At my J1, they offered to convert me to [full-time].&#8221; The person went on to explain how their entire team—many with pregnant wives—had been fired after relocating, then rehired a year later at lower pay. &#8220;These companies hate us," he said.
One user summed up what many have come to realize: "Companies don't care about you as a person, and managers will let you go if they think it makes their lives easier or they can pad their own pockets. I've got kid #3 on the way and I'm extremely hesitant to let anyone in on it professionally. Companies want you to be 150% loyal but refuse any loyalty back."
For this developer, the lesson was this: job security comes from diversifying income streams, not from company loyalty. And judging by the comments, he's far from alone in that realization.
Read Next:
<ul>
<li>This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

A Senior Developer Asked For A Raise After Having A Baby Learned A Hard Lesson About Job Security. Vowed To Never Rely On Just One Job Again

<a href="https://www.benzinga.com/topic/stephanie-link">Stephanie Link</a>, Chief Investment Strategist at Hightower Advisors, on Wednesday shared her insights on key stocks, emphasizing Amazon's growing dominance, Palo Alto Networks Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) cybersecurity potential, Target Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) recovery efforts and NextEra Energy Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) valuation opportunity.
What To Know: Link highlighted Amazon's <a href="https://in.benzinga.com/analyst-ratings/analyst-color/25/02/43847764/amazon-tightens-grip-e-commerce-accelerates-jpmorgans-best-idea-2025">expanding market share</a>, which grew by 410 basis points last quarter, with improving profitability. She expects further acceleration in the latter half of the year despite capacity constraints.
Read Also: <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">Amazon Analyst Ratings</a>
On Palo Alto Networks, she sees a $15 billion annualized revenue opportunity in platformization and views it as a stronger long-term play compared to CrowdStrike Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), which she recently sold.
Target, down 24% since February, <a href="https://www.benzinga.com/personal-finance/25/03/44360075/retail-giant-target-which-relies-on-china-for-30-of-its-merchandise-warns-of-profit-hit-as-trumps-trade-war-bites">has struggled with product mix</a> but is showing signs of recovery, particularly in discretionary spending. Link says sustained improvement could restore investor confidence.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44403637/fed-holds-rates-while-growth-forecasts-slip-inflation-projections-rise">Fed Holds Rates While Growth Forecasts Slip, Inflation Projections Rise</a>
Meanwhile, she initiated a position in Nextera Energy, noting its historically high valuation but seeing an opportunity now that it trades at 18 times price-to-sales. She praised its joint venture with GE Vernova Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) in natural gas and data centers.
Additionally, Link named Boeing her top 2025 stock due to leadership changes and improving execution. She remains bullish on Palo Alto, Gap Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) turnaround under Richard Dixon, Target's resilience and Snowflake Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) AI-driven growth under new management.
Read now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44399554/analysts-see-upside-for-95-of-sp-500-stocks-how-nvidia-tesla-stack-up" target="_blank" rel="noreferrer noopener">Analysts See Upside For 95% Of S&amp;P 500 Stocks: How Nvidia, Tesla Stack Up</a></li>
</ul>
Photo courtesy of Hightower Advisors

CRWD

PANW

SNOW

Stephanie Link: 'Amazon's Market Share is Soaring' – Insights On Amazon, Palo Alto Networks, Target & Nextera Energy

Management

NOV Promotes Jose Bayardo To President & COO And Rodney Reed To Senior Vice President & CFO

13 analysts have shared their evaluations of Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $98.62, a high estimate of $110.00, and a low estimate of $90.00. Witnessing a positive shift, the current average has risen by 5.28% from the previous average price target of $93.67.
<img src="https://www.benzinga.com/files/images/story/2025/1742418025_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Insmed. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$101.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Insmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Insmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Insmed's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Insmed analyst ratings.</a>
<h2>Discovering Insmed: A Closer Look</h2>
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
<h3>Breaking Down Insmed's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Insmed's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 24.79%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Insmed's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -225.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Insmed's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -61.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Insmed's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -11.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Insmed's debt-to-equity ratio stands notably higher than the industry average, reaching 4.03. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

INSM

Expert Outlook: Insmed Through The Eyes Of 13 Analysts

Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) has outperformed the market over the past 5 years by 21.93% on an annualized basis producing an average annual return of 40.39%. Currently, Parker Hannifin has a market capitalization of $81.12 billion. 
Buying $1000 In PH: If an investor had bought $1000 of PH stock 5 years ago, it would be worth $6,457.67 today based on a price of $630.01 for PH at the time of writing.
<h3>Parker Hannifin's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742418011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Parker Hannifin 5 Years Ago Would Be Worth Today

<ul>
<li>Gross crypto revenues of $1.023 billion - $1.271 billion</li>
<li>Net loyalty revenues of $8.5 million - $9.9 million</li>
</ul>

Guidance

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Expects Q1 Total Revenues Of $1.03B - $1.28B

ProAssurance Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) shares are soaring in Wednesday&#8217;s after-hours session following the company announcement that it will be <a href="https://www.benzinga.com/pressreleases/25/03/b44405938/the-doctors-company-to-acquire-proassurance-corporation-for-25-00-per-share-in-cash">acquired by The Doctors Company</a>.
What Happened: After market close on Wednesday, ProAssurance announced it entered into a definitive agreement to be acquired by physician-owned medical malpractice insurer The Doctors Company for $25 per share in cash.
The deal has a transaction value of approximately $1.3 billion and represents a 60% premium to ProAssurance&#8217;s stock price at the close on Tuesday. 
&#8220;This transaction will deliver significant value to our shareholders,&#8221; said Ned Rand, president and CEO of ProAssurance.
&#8220;Bringing the strengths and capabilities of our companies together now will allow our teams to continue to serve today&#8217;s healthcare providers with the necessary scale and breadth of capabilities.&#8221;
Check This Out: <a href="https://www.benzinga.com/25/03/44405183/march-madness-2025-how-to-watch-betting-odds-and-the-one-stat-that-could-determine-a-winner">March Madness 2025: How To Watch, Betting Odds And The One Stat That Could Determine A Winner</a>
ProAssurance&#8217;s board unanimously approved the transaction. The deal is expected to close in the first half of 2026. Upon closing, ProAssurance&#8217;s common stock will no longer be listed on the New York Stock Exchange and the company will become a wholly-owned subsidiary of The Doctors Company.
&#8220;Healthcare is a team sport and the teams are getting larger. In order to provide them the best imaginable service requires a mission-based company with nationwide scale, resources and dedication to all medical professions and healthcare providers,&#8221; said Richard Anderson, chairman and CEO of The Doctors Company. 
PRA Price Action: <a href="http://benzinga.com/quote/pra">ProAssurance shares</a> were up 50.13% after-hours, trading at $23.33 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

ProAssurance Stock Jumps 50% On Takeover Deal With The Doctors Company

Bakkt Explores Strategic Alternatives, Including Potential Sale Or Wind-down, For Its Loyalty Business Segment

The divestiture is expected to streamline operations by reducing operating expenses by $3.8 million annually and freeing up approximately $3.0 million of capital held for regulatory reserves.
The divestiture is expected to streamline operations by reducing operating expenses by $3.8 million annually and freeing up approximately $3.0 million of capital held for regulatory reserves.

Asset Sales

Bakkt Agrees To Sell Qualified Custodian Subsidiary, Bakkt Trust Company, To ICE For Cash Of $1.5M Plus Assumption Of Regulatory Capital Requirement And Certain Costs

Earnings

X Financial Q4 Adj EPADS $1.16, Sales $234.1M

Press Releases

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza  mRNA Vaccine Program

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Events

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

JMP Securities

Leerink Partners

B of A Securities

SVB Securities

Comments

CureVac

CureVac (CVAC) 옵션

CureVac (NASDAQ:CVAC) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌